Minaris Advanced Therapies, a leading global contract development and manufacturing organization and testing provider, has announced the opening of its new GMP manufacturing facility in Munich, Germany. The facility, located in Taufkirchen, strengthens Minaris’ global manufacturing network and reinforces its position as a trusted partner in advancing cutting-edge therapies from concept to commercialization.
Health Technology Insights: ZOIA Healthcare Acquires Lil’s Dietary a Commitment to Rare Metabolic Disease Community
Minaris’ new facility builds on over 10 years of experience in both the clinical and commercial manufacture of advanced therapies. The facility is built to support technology transfer of commercial advanced therapies into Europe. The new facility enabled the consolidation of process and analytical development, and all the legacy manufacturing operations onto a single site. Located just minutes from the Munich International Airport, the new facility offers a strategic logistical advantage for clients across Europe and beyond.
The site includes:
- Six Grade B/A cleanrooms for aseptic manufacturing
- One Grade C cleanroom designed for bioreactors and closed systems with convertible capability to A/B grade
- Customizable cleanroom configurations and 224 m² (2411 ft2) of expansion space
- Independently controlled HVAC systems for each cleanroom suite to reduce downtime and enable true parallel production activities
- Dedicated process development and quality control laboratories
- Cryopreservation and storage facilities
- Enhanced alarming and safety systems
Health Technology Insights: Surgical Safety Tech Adds Kinematic Data to Boost Proficiency
“The opening of this facility marks an important milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies globally,” said Dr. Orla Cloak, Chief Executive Officer of Minaris Advanced Therapies. “It enhances our European footprint and enhances our ability to meet client needs with speed, quality, and scalability.”
“This facility embodies our shared vision for the future of cell and gene therapy manufacturing—scalable, flexible, and globally integrated,” said Iain Baird, Chairman of the Board, Minaris Advanced Therapies.”The seamless transition into this new facility is a testament to the dedication of our team in Germany and the commitment Minaris Advanced Therapies has to bring long-term value to clients and patients worldwide.”
Health Technology Insights: C8 Health Raises $12 Million Series A for the Healthcare Industry’s First AI-Powered
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- PR Newswire
